

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5489751

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ENDO PHARMACEUTICALS INC.	05/29/2014
RECEIVING PARTY DATA	
Name:	ASANA BIOSCIENCES, LLC
Street Address:	997 LENOX DRIVE
Internal Address:	SUITE 220, PRINCETON PIKE CORPORATE CENTER
City:	LAWRENCEVILLE
State/Country:	NEW JERSEY
Postal Code:	08648
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16392889
CORRESPONDENCE DATA	
Fax Number:	(215)656-3301
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	215-656-3300
Email:	pto.phil@dlapiper.com
Correspondent Name:	IP GROUP OF DLA PIPER LLP (US)
Address Line 1:	ONE LIBERTY PLACE
Address Line 2:	1650 MARKET STREET, SUITE 4900
Address Line 4:	PHILADELPHIA, PENNSYLVANIA 19103
ATTORNEY DOCKET NUMBER:	ASN-16-1583WO-US1-CON-CON
NAME OF SUBMITTER:	WILLIAM L. BARTOW
SIGNATURE:	/williamlbartow/
DATE SIGNED:	04/24/2019
Total Attachments: 11	
source=Endo_to_Asana#page1.tif	
source=Endo_to_Asana#page2.tif	
source=Endo_to_Asana#page3.tif	
source=Endo_to_Asana#page4.tif	

source=Endo_to_Asana#page5.tif
source=Endo_to_Asana#page6.tif
source=Endo_to_Asana#page7.tif
source=Endo_to_Asana#page8.tif
source=Endo_to_Asana#page9.tif
source=Endo_to_Asana#page10.tif
source=Endo_to_Asana#page11.tif

ASSIGNMENT

WHEREAS, Endo Pharmaceuticals Inc., a Delaware Corporation having an address at 1400 Atwater Drive, Malvern, PA 19355 (hereinafter referred to as "Assignor"), is the owner of patent applications and/or Letters Patent listed on the attached Schedule A; and

WHEREAS, Asana BioSciences, LLC, a Delaware Limited Liability Company (hereinafter referred to as "Assignee"), is desirous of acquiring the entire right, title and interest in and to said patent applications and Letters Patent in the United States and all foreign countries granted therefor and thereon, including any continuations, divisions, renewals, reissues and extensions thereof and the inventions covered thereby;

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor has sold, assigned, transferred and set over, and by these presents does irrevocably sell, assign, transfer and set over, unto Assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned patent applications and Letters Patent set forth on Schedule A attached hereto and the inventions covered thereby, and in and to any and all direct and indirect divisions, continuations and continuations-in-part of said applications, and any and all Letters Patent in the United States and all foreign countries which may be granted therefor and thereon, and reissues, reexaminations and extensions of said Letters Patent, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent may be granted and/or extended, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

AND for the same consideration, Assignor hereby covenants and agrees to and with Assignee, its successors, legal representatives and assigns, that Assignor will sign all papers and documents as may be necessary to effect the assignment and transfer contemplated hereby of the patent applications and Letters Patent set forth on Schedule A.

AND Assignor hereby requests the Commissioner of Patent and Trademarks to issue said Letters Patent of the United States to Assignee, as Assignee of said inventions and the Letters Patent to be issued thereon, for the sole use and benefit of Assignee, its successors, legal representatives and assigns.

AND Assignor hereby grants the following individuals the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document:

VENABLE LLP

All practitioners at Customer Number 26694.

For Endo Pharmaceuticals Inc.:


Date: 5/29/2014

[Signature]
 Signature
Rajiv De Silva
 Typed Name
President and Chief Executive Officer
 Title

United States of America)
 State of Pennsylvania) ss.:
 County of Chester)

On this 29th day of May, 2014, before me personally came Rajiv De Silva, to me known to be the individual described in and who executed the foregoing instrument, and acknowledged execution of the same.


[Signature]
 Notary Public



[Signature Page to Assignment of Patent Rights]

For Asana BioSciences, LLC:

Date: 5/23/14


Signature

Vikram Patel

Typed Name

Authorized Signatory

Title

United States of America)
State of) ss.:
County of)

See attached

On this _____ day of _____, 2014, before me personally came _____, to me known to be the individual described in and who executed the foregoing instrument, and acknowledged execution of the same.

Notary Public


ACKNOWLEDGMENT

STATE OF CALIFORNIA)
)ss
COUNTY OF ORANGE)

On May 28, 2014, before me, M. Haslip, Notary Public, personally appeared VIKRAM PATEL, who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.



M. Haslip

Notary Public

(Seal)

Schedule A

COUNTRY	TITLE	SERIAL NO PATENT NO.	FILING DATE ISSUE DATE
WO (PCT)	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	US12/025759	2/18/2012
AU	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	2012219254	2/18/2012
JP	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	2013-554666	2/18/2012
RU	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	2013142433	2/18/2012
MX	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	MX/A/2013/09537	2/18/2012
KR	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	10-2013-7023468	2/18/2012
US	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	61/444,379	2/18/2011
IN	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	6488/DELNP/2013	2/18/2012
IL	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	227967	2/18/2012
EP	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	12706985.4	2/18/2012
CN	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	201280016004.8	2/18/2012
BR	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	BR1120130208740	2/18/2012
ZA	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	2013/05820	2/18/2012
US	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	13/400,039	2/18/2012

COUNTRY	TITLE	SERIAL NO PATENT NO.	FILING DATE ISSUE DATE
CA	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	2,826,648	2/18/2012
UA	AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN	201311103	2/18/2012
US	BIARYL IMIDAZOLE DERIVATIVES FOR REGULATING CYP17 (As Amended)	13/632,007	9/30/2012
US	COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS	61/875,963	9/10/2013
WO (PCT)	CYCLOHEXYLAMINES	US12/061703	10/24/2012
US	CYCLOHEXYLAMINES	61/550,489	10/24/2011
US	CYCLOHEXYLAMINES	13/659,694 8,685,418	10/24/2012 4/1/2014
US1	CYCLOHEXYLAMINES	14/220,381	3/20/2014
WO (PCT)	IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER (As Amended)	US12/057908	9/28/2012
US	IMIDAZOLE DERIVATIVES	61/541,634	9/30/2011
JP	IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER (As Amended)	US12/057908	9/28/2012
EP	IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER (As Amended)	12775389.5	9/28/2012
CA	IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER (As Amended)	US12/057908	9/28/2012
US	P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS	61/916,499	12/16/2013

PATENT
REEL: 040345 FRAME: 0404
PATENT
REEL: 048980 FRAME: 0512

COUNTRY	TITLE	SERIAL NO PATENT NO.	FILING DATE ISSUE DATE
US	PROTEIN-POLYMER DRUG CONJUGATES	61/975,290	4/4/2014
US	PROTEIN-POLYMER DRUG CONJUGATES	61/890,065	10/11/2013
US	PYRIDINE DERIVATIVES	13/795,771	3/12/2013
US	PYRIDINE DERIVATIVES	14/078,612	11/13/2013
US	PYRIDINE DERIVATIVES	13/632,006	9/30/2012
US	PYRIDINE DERIVATIVES	61/541,621	9/30/2011
JP	PYRIDINE DERIVATIVES	US12/057899	9/28/2012
EP	PYRIDINE DERIVATIVES	US12/057899	9/28/2012
CA	PYRIDINE DERIVATIVES	US12/057899	9/28/2012
WO (PCT)	PYRIDINE DERIVATIVES	US12/057899	9/28/2012
WO (PCT)	PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF (As Amended)	US12/051980	8/23/2012
EP	PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF (As Amended)	12756865.7	8/23/2012
US	PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF	61/526,525	8/23/2011
MX	PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF (As Amended)	US12/051980	8/23/2012
JP	PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF (As Amended)	US12/051980	8/23/2012

PATENT
REEL: 040345 FRAME: 0405
PATENT
REEL: 048980 FRAME: 0513

COUNTRY	TITLE	SERIAL NO PATENT NO.	FILING DATE ISSUE DATE
US	PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF	13/592,511	8/23/2012
US	PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF	14/244,183	4/3/2014
BR	PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF (As Amended)	BR112014003981-0	8/23/2012
CA	PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF (As Amended)	US12/051980	8/23/2012
CN	PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF (As Amended)	US12/051980	8/23/2012
IL	PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF (As Amended)	231082	8/23/2012
WO (PCT)	QUINAZOLINES AND AZAQUINAZOLINES	US14/33727	4/11/2014
US	QUINAZOLINES AND AZAQUINAZOLINES	61/811,408	4/12/2013
US	SELF-IMMOLATIVE LINKERS CONTAINING MADELIC ACID DERIVATIVES, DRUG-LIGAND CONJUGATES FOR TARGETED THERAPIES AND USES THEREOF	61/877,439	9/13/2013
US	SUBSTITUTED AMINO- PYRIMIDINE DERIVATIVES	13/957,470	8/2/2013
US	SUBSTITUTED AMINO- PYRIMIDINE DERIVATIVES	61/678,694	8/2/2012
TW	SUBSTITUTED AMINO- PYRIMIDINE DERIVATIVES	102127708	8/2/2013
WO (PCT)	SUBSTITUTED 5-(QUINAZOLIN-2- YL) PYRIMIDIN-2-AMINE DERIVATIVES USEFUL AS PI3K/MTOR INHIBITORS FOR THE TREATMENT OF CANCER (As Amended)	US13/053327	8/2/2013

COUNTRY	TITLE	SERIAL NO PATENT NO.	FILING DATE ISSUE DATE
US	SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES	61/501,901	6/28/2011
US	SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES	13/285,227 8,440,662	10/31/2011 5/14/2013
US	SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES	13/787,946	3/7/2013
US	SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES	14/076,765	11/11/2013
WO (PCT)	SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES	US11/058584	10/31/2011
US	SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES	61/408,620	10/31/2010
TW	USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS	102129228	8/15/2013
US	USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS	61/683,518	8/15/2012
US	USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS	61/718,072	10/24/2012
US	USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS	13/967,389	8/15/2013
WO (PCT)	USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS	US13/055029	8/15/2013
US	USE OF CYCLOHEXYLAMINES IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS	61/683,519	8/15/2012
N/A	5T4-TARGETED IMMUNOFUSION MOLECULE AND METHODS	61/835,858	6/17/2013

COUNTRY	TITLE	SERIAL NO PATENT NO.	FILNG DATE ISSUE DATE
N/A	SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE	US11/058584	10/31/2011
N/A	SUBSTITUTED AMINO- PYRIMIDINE DERIVATIVES	102127708	8/2/2013

RECORDED: 11/16/2016
RECORDED: 04/24/2019

PATENT
REEL: 040345 FRAME: 0408
PATENT
REEL: 048980 FRAME: 0516